Siddharth Mittal'un ücretlendirmesi Biocon'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹14b
Jun 30 2024	n/a	n/a	₹16b
Mar 31 2024	₹57m	₹57m	₹10b
Dec 31 2023	n/a	n/a	₹12b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹48m	₹48m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹6b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹42m	₹42m	₹6b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹43m	₹43m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹7b
Mar 31 2020	₹49m	₹31m	₹8b

Tazminat ve Piyasa: Siddharth 'ın toplam tazminatı ($USD 672.19K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 720.32K ).

Tazminat ve Kazançlar: Siddharth 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Siddharth Mittal (46 yo)

5yrs

Görev süresi

₹57,310,000

Tazminat

Mr. Siddharth Mittal, BCom, CA, CPA has been CEO and Director of Biocon Limited since December 1, 2019. He has been Managing Director of Biocon Limited since April 01, 2020 and served as its Joint Managing...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	46.1yrs	₹38.43m	40.49% ₹ 167.9b
Siddharth Mittal	MD, CEO & Director	5yrs	₹57.31m	0.069% ₹ 287.8m
Peter James Bains	Group Chief Executive Officer	1.3yrs	₹1.91m	Veri yok
Mukesh Kamath	Chief Financial Officer	less than a year	Veri yok	Veri yok
Arun Gupta	Head of Operations	1.7yrs	Veri yok	Veri yok
Atanu Roy	Group Chief Information Officer	4.3yrs	Veri yok	Veri yok
Saurabh Paliwal	Head of Investor Relations	2.3yrs	Veri yok	Veri yok
Mayank Verma	Company Secretary & Compliance Officer	5.4yrs	₹5.75m	Veri yok
Seema Ahuja	Global Head of Communications & Corporate Brand	no data	Veri yok	Veri yok
Maninder Puri	Head of Human Resources	no data	Veri yok	Veri yok
Paul Thomas	Chief Commercial Officer	no data	Veri yok	Veri yok
Abhijit Zutshi	Commercial Head of Biocon Global Generics	no data	Veri yok	0.019% ₹ 77.0m

2.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: BIOCON 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	46.1yrs	₹38.43m	40.49% ₹ 167.9b
Siddharth Mittal	MD, CEO & Director	5yrs	₹57.31m	0.069% ₹ 287.8m
Ravi Mazumdar	Non-Executive Non-Independent Director	24.3yrs	₹6.23m	0.44% ₹ 1.8b
Bobby Parikh	Independent Non-Executive Director	6.4yrs	₹7.81m	Veri yok
Naina Lal Kidwai	Additional Non-Executive Independent Director	2.7yrs	₹6.24m	Veri yok
Satish Garg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nicholas Haggar	Independent Director	1.1yrs	₹5.20m	Veri yok
Shashank Joshi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Rekha Menon	Independent Director	1.4yrs	₹5.70m	Veri yok
Eric Mazumdar	Non-Executive Director	3.1yrs	₹5.57m	0.27% ₹ 1.1b
John Petrie	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Atul Dhawan	Non-Executive and Independent Director	less than a year	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BIOCON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 21:35
Gün Sonu Hisse Fiyatı	2024/12/26 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Biocon Limited 42 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Meeta Shetty	Asian Markets Securities Private Limited
Harith Ahamed	Avendus Spark
Kunal Randeria	Axis Capital Limited

Biocon Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Biocon Limited, Annual General Meeting, Aug 09, 2024

Insider recently sold ₹5.3m worth of stock

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Recent updates

U.S. FDA Approves Biocon Biologics' YESINTEK, Bmab 1200 Biosimilar to J&J's Stelara (Ustekinumab)

Consensus EPS estimates fall by 20%

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹13m worth of stock

Insider recently sold ₹40m worth of stock

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insider recently sold ₹4.2m worth of stock

Consensus forecasts updated